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Background: Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide.
In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study
were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and
regional differences in stage distribution and survival of melanoma patients.
Methods: Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented
in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods,
joinpoint regression, logistic regression and relative survival.
Results: The number of annually documented cases increased by 53.2% between 2002 (N = 4 779) and 2011 (N = 7
320). There was a statistically significant continuous positive trend in the proportion of stage UICC I cases diagnosed
between 2002 and 2011, compared to a negative trend for stage UICC II. No trends were found for stages UICC III and
IV respectively. Age (OR 0.97, 95% CI 0.97–0.97), sex (OR 1.18, 95% CI 1.11–1.25), date of diagnosis (OR 1.05, 95%
CI 1.04–1.06), ‘diagnosis during screening’ (OR 3.24, 95% CI 2.50–4.19) and place of residence (OR 1.23, 95% CI
1.16–1.30) had a statistically significant influence on the tumour stage at diagnosis. The overall 5-year relative
survival for invasive cases was 83.4% (95% CI 82.8–83.9%).
Conclusions: No distinct changes in the distribution of malignant melanoma tumour stages among those aged 35
and older were seen that could be directly attributed to the introduction of skin cancer screening in 2008.
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Malignant melanoma occurs primarily in fair-skinned
populations, with almost 80% of new cases worldwide
occurring in North America, Europe, Australia and New
Zealand [1]. It is the fourth most common cancer in
Australia (age-standardised incidence rate 34.9 per 100
000, World Standard Population), the sixth most com-
mon cancer in North America (13.8 per 100 000) and
the seventh most common cancer in the European
Union (10.2 per 100 000), as well as in Germany (11.4
per 100 000) [2]. Although the age-standardised
incidence rate in Germany increased considerably more
between 2006 and 2008 than in other years since 1999,
malignant melanoma-related mortality has remained
relatively stable over the same period [3].
Malignant melanoma can be treated with a very good
prognosis if it is detected in the early stages (Union
internationale contre le cancer (UICC) 0-I). However, in
advanced stages, therapies which were available up until
2011 had limited effect.
A screening program for skin cancer was set up in the
USA in 1985, with national screening and educational
programs having expanded to all 50 states [4]. Although
examinations for early detection of skin cancer were
already offered in Germany since 1971 [5], Germany was
the first country in Europe to introduce nationwide skin
cancer screening in 2008 [6]. Since 1st July 2008, all
men and women aged 35 years and older have been
eligible for a skin examination by a dermatologist or spe-
cially certified physician every two years. However, the
screening is not organised and there is no invitation to
attend. According to data reported for Germany, partici-
pation among those aged 35 years and older was around
30% between 2008 and 2010 [7, 8].
A regional German pilot project in the northern fed-
eral state of Schleswig-Holstein conducted between July
2003 and June 2004 provided preliminary evidence for
the effectiveness of screening [9]. Changes in TNM
stage-specific incidence were shown, with an increase in
prognostically favourable malignant melanoma, includ-
ing in situ and pT1. The incidence of advanced malig-
nant melanoma, including pT2, pT3 and, for women
only, pT4 substantially declined [9, 10].
We analysed data from 61 895 malignant melanoma
patients diagnosed between 2002 and 2011 and
documented in German clinical cancer registries. This
period was prior to the introduction of targeted therap-
ies. Clinical characteristics of malignant melanoma were
investigated and proportional changes, as well as demo-
graphic and regional differences in the distribution of
tumour stages were described over time. We examined
the survival of melanoma patients, overall and stratified
by age, sex, UICC stage, ‘diagnosis during screening’ and
place of residence.Methods
A population-based clinical registry structure in eastern
Germany and Bavaria has been in existence for about two
decades, while in the other German federal states these
registries are predominantly still in the development stage.
Population-based clinical registries, as opposed to hospital-
based clinical registries, have a regional focus, registering
cases resident in their respective catchment areas. Particu-
larly in the five eastern German federal states and Bavaria,
it is mandatory that data of cases registered at the clinical
cancer registries are then passed on to the respective epi-
demiological state registry. The epidemiological cancer
registries in Germany have nationwide coverage.
In June 2013, all clinical cancer registries in Germany
were contacted by the Working Group of German Tumour
Centres and Clinical Cancer Registries (ADT) and were
asked to provide anonymised data on malignant melanoma
patients diagnosed between 2002 and 2011. Data from 24
population-based registries and four hospital-based regis-
tries from Baden-Württemberg, Bavaria, Brandenburg,
Hesse, Mecklenburg-Western Pomerania, North Rhine-
Westphalia, Rhineland-Palatinate, Saxony, Saxony-Anhalt
and Thuringia were included in the analyses. Regarding
hospital-based clinical cancer registries, the place of
residence of patients did not necessarily correspond to the
federal state of the registry where the case was registered.
Our analyses therefore include data on malignant melan-
oma cases resident in all federal states in Germany.
For each of the federal states Bavaria, Brandenburg,
Mecklenburg-Western Pomerania, Saxony, Saxony-Anhalt
and Thuringia, the number of invasive cases included in
this analysis represented approximately 85% of all the newly
diagnosed cases reported by the association of population-
based epidemiological cancer registries (GEKID) during
each year between 2002 and 2011 [11]. For all other federal
states and the region Westphalia-Lippe, the proportion was
less than 10%, respectively. Of the 50 446 patients with in-
vasive tumours included in these analyses, 41 102 (81%)
lived in the six federal states of Bavaria, Brandenburg,
Mecklenburg-Western Pomerania, Saxony, Saxony-Anhalt
and Thuringia.
Information was available on age, sex, place of resi-
dence, vital status, date of diagnosis, ‘diagnosis during
screening’ (i.e. whether or not the diagnosis was made
during screening) and TNM characteristics. UICC stages
were derived from TNM according to the 6th edition of
TNM Classification of Malignant Tumours [10], includ-
ing stage UICC 0 (in situ), I, II (both invasive without
metastases), III (invasive with regional lymph node me-
tastases) and IV (invasive with distant metastases). Cases
where the UICC stage could not be determined were
classified as UICC X. pT stages are classified according
to the following tumour thicknesses: pT1 (≤1 mm), pT2
(1.01–2.0 mm), pT3 (2.01–4.0 mm) and pT4 (>4 mm). It
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classification between 2001 and 2002, with the tumour
thickness of 1.5–2.0 mm being reclassified from stage
UICC II to stage UICC I.
Inclusion and exclusion criteria
Both population-based (n = 24) and hospital-based clin-
ical cancer registries (n = 7) provided data. All malignant
melanoma cases that were diagnosed between 2002 and
2011, with localisation of ICD-O C44.0-C44.9 (ICD-10:
C43.0-C43.9 and D03.0-D03.9) and histology of ICD-O
M8720-M8790, were included [12]. Only cases aged
15 years and above at diagnosis were included in the
analysis, as younger cases were registered by a separate
childhood cancer registry. Additionally, only primary
melanoma diagnoses were considered. Three registries
that did not document data for the entire period of ob-
servation (2002–2011, regarding date of diagnosis) were
excluded from the analyses. Cases were also excluded
when the date of diagnosis documented in the registry
was identical to the date of death retrieved from a death
certificate (death certificate only, DCO) and when the sex
of the patient was not known (Additional file 1: Figure S1).
Statistical methods
Descriptive analyses as well as logistic regressions and sur-
vival estimations were performed. Patients were categorised
into the age groups 15–34 years, 35–49 years, 50–64 years,
65–79 years and over 79 years. Additionally, to emphasise
the difference between younger and older patients, the age
groups were further aggregated into the categories 15–34
years, 35–64 years and 65 years and older.
Absolute numbers and proportions of UICC tumour
stages were described over time (2002–2011).
Joinpoint regression
Tests for trends in age-specific proportions of UICC stages
over time were performed using joinpoint regression. This
method describes changing trends over successive segments
of time, and the extent of increase or decrease within each
segment [13]. We investigated whether the identified trends
were continuous for the complete time period (2002–2011)
or whether changing trends for specific segments could be
identified. APC (annual percent change) and the respective
95% confidence intervals were estimated to indicate the
magnitude of the trends.
Logistic regression
Univariable and multivariable binary logistic regression [14]
was used to model the associations between the chance of
being diagnosed at stage UICC I vs. UICC II–IV and poten-
tial influencing factors, including age, sex, date of diagnosis,
‘diagnosis during screening’ and geographical area of resi-
dence (eastern Germany including Berlin, Brandenburg,Mecklenburg-Western Pomerania, Saxony, Saxony-Anhalt
and Thuringia vs. western Germany including Baden-
Württemberg, Bavaria, Bremen, Hamburg, Hesse, Lower
Saxony, North Rhine-Westphalia, Rhineland-Palatinate,
Saarland and Schleswig Holstein). In the logistic regression,
cases with UICC 0 or UICC X and cases from registries
that did not collect any data for the variable ‘diagnosis dur-
ing screening’ (registries with 100% missing values for the
variable ‘diagnosis during screening’) were excluded. Since
only men and women aged 35 years and older are eligible
for skin cancer screening, cases diagnosed at younger ages
were also excluded from the logistic regression models.
Variable selection was performed such that only vari-
ables with significant influence in the univariable models
were included in the multivariable model. The variable
selection was verified by Wald test and bootstrapping
[15]. The bootstrap procedure was performed with 1 000
runs and 100*(1-α)% confidence intervals were estimated
from the α/2 and (1-α/2) percentile of the 1 000 result-
ing parameter estimators.
In order to assess the impact of missing values for the
variable ‘diagnosis during screening’, the multivariable lo-
gistic regression models were also performed as
complete case analysis (i.e. exclusion of all cases without
information about whether the diagnosis was made dur-
ing screening). Additionally, to include all available pa-
tient data, a multiple imputation [16] for the variable
‘diagnosis during screening’ was performed using a dis-
criminant function by fully conditional specification
method [17]. A logistic regression model was also con-
ducted without the ‘diagnosis during screening’ variable.
Survival estimation
Only population-based registries were included in the sur-
vival analysis in order to ensure consistency with regard to
how information on follow-up was captured and to per-
form a population-based analysis. Survival estimations were
carried out based on the Nelson-Aalen estimator [18] with
the cohort approach. Relative survival rates were derived
using the Ederer II method [19, 20]. The median survival
was estimated as the lowest survival time where the overall
survival function was ≤ 0.5. Stratified survival for patients
with invasive tumours (UICC 0 excluded) was estimated ac-
cording to age group (15–34, 35–49, 50–64, 65–79 and
over 79 years), sex, UICC stage, ‘diagnosis during screening’
and place of residence. Differences between the relative sur-
vival for different strata were tested by pairwise Log-rank
test [21].The following reference categories were chosen -
age: 65–79 years, sex: female, UICC stage: I, ‘diagnosis dur-
ing screening’: no, place of residence: eastern Germany.
Confidence intervals for specific survival rates were esti-
mated by log-log transformation [22] of specific standard
errors according to Greenwood's formula [23]. Even though
the Nelson-Aalen estimator already takes censored values
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can bias survival estimates. Multiple imputation of vital sta-
tus for cases lost to follow-up, using a cox regression
model, was therefore applied according to Carpenter and
Kenward [24].
All test results were considered statistically significant
if p < 0.05. Descriptive analyses, logistic regression and
relative survival were performed with SAS statistical
analysis software (Version 9.3, Cary, North Carolina,
USA). Joinpoint regression was performed with the Join-
point Regression Program (Version 4.2.0.2, Statistical
Research and Applications Branch, National Cancer In-
stitute, Bethesda, Maryland, USA).
Results
Study Population
A total of 61 895 cases with a primary malignant melanoma
registered in 24 population-based and four hospital-basedFig. 1 Regional distribution of malignant melanoma cases by place of residclinical cancer registries in Baden-Württemberg, Bavaria,
Brandenburg, Hesse, Mecklenburg-Western Pomerania,
North Rhine-Westphalia, Rhineland-Palatinate, Saxony,
Saxony-Anhalt and Thuringia were included in the analyses
(Fig. 1).
The number of annually documented melanoma cases
(including UICC Stage 0 and X) increased by 53.2% over
time, from 4 779 in 2002 to 7 320 in 2011. The largest
increase in documented cases occurred between 2007
(6 134 cases) and 2008 (7 229 cases) (Table 1). The num-
ber of cases diagnosed with stage UICC 0 increased con-
tinuously over time. Stage UICC I also increased over
time, with the largest increase in number of cases occurring
between 2007 and 2008. Stage UICC II showed a decline in
number of cases (2002: 814 cases; 2011: 720 cases), al-
though from 2003 onwards the number of cases remained
relatively constant. Stage UICC III showed an increase in
number of cases (2002: 260 cases; 2011: 392 cases) whileence between 2002 and 2011 in Germany, N = 61 895
Table 1 Malignant melanoma patients diagnosed between 2002 and 2011 by age at diagnosis, sex, year of diagnosis and UICC
stage, N = 61 895
Stage Total
Stratum UICC 0 UICC I UICC II UICC III UICC IV UICC X N (%)b
N (%) {%}a
Total 11 449 (18.5) 25 681 (41.5) 7 352 (11.9) 3 555 (5.7) 1 359 (2.2) 12 499 (20.2) 61 895 (100.0)
{67.7} {19.4} {9.4} {3.6}
Age at diagnosis (years) 15–34 764 (15.5) 2 562 (52.1) 346 (7.0) 252 (5.1) 48 (1.0) 942 (19.2) 4 914 (7.9)
{79.9} {10.8} {7.9} {1.5}
35–49 1 811 (15.2) 5 864 (49.3) 965 (8.1) 712 (6.0) 216 (1.8) 2 320 (19.5) 11 888 (19.2)
{75.6} {12.4} {9.2} {2.8}
50–64 2 913 (17.4) 7 385 (44.1) 1 713 (10.2) 1 036 (6.2) 401 (2.4) 3 296 (19.7) 16 744 (27.1)
{70.1} {16.3} {9.8} {3.8}
65–79 4 704 (21.2) 8 167 (36.9) 3 092 (14.0) 1 243 (5.6) 521 (2.4) 4 419 (20.0) 22 146 (35.8)
{62.7} {23.7} {9.5} {4.0}
≥80 1 257 (20.3) 1 703 (27.5) 1 236 (19.9) 312 (5.0) 173 (2.8) 1 522 (24.5) 6 203 (10.0)
{49.7} {36.1} {9.1} {5.1}
Sex Male 5 165 (17.0) 12 542 (41.2) 3 807 (12.5) 2 065 (6.8) 823 (2.7) 6 065 (19.9) 30 467 (49.2)
{65.2} {19.8} {10.7} {4.3}
Female 6 284 (20.0) 13 139 (41.8) 3 545 (11.3) 1 490 (4.7) 536 (1.7) 6 434 (20.5) 31 428 (50.8)
{70.2} {18.9} {8.0} {2.9}
Year of diagnosis 2002 612 (12.8) 1 939 (40.6) 814 (17.0) 260 (5.4) 128 (2.7) 1 026 (21.5) 4 779 (7.7)
{61.7} {25.9} {8.3} {4.1}
2003 674 (14.0) 2 095 (42.8) 642 (13.1) 296 (6.0) 136 (2.8) 1 051 (21.4) 4 900 (7.9)
{66.1} {20.3} {9.3} {4.3}
2004 805 (15.5) 2 187 (41.5) 742 (14.1) 327 (6.2) 130 (2.5) 1 074 (20.4) 5 271 (8.5)
{64.6} {21.9} {9.7} {3.8}
2005 897 (16.1) 2 371 (42.1) 745 (13.2) 355 (6.3) 133 (2.4) 1 129 (20.0) 5 638 (9.1)
{65.8} {20.7} {9.9} {3.7}
2006 1 052 (18.0) 2 366 (39.8) 738 (12.4) 360 (6.1) 145 (2.4) 1 272 (21.4) 5 940 (9.6)
{65.6} {20.4} {10.0} {4.0}
2007 1 121 (18.7) 2 553 (41.6) 744 (12.1) 390 (6.4) 150 (2.4) 1 166 (19.0) 6 134 (9.9)
{66.5} {19.4} {10.2} {3.9}
2008 1 357 (19.2) 3 079 (42.6) 761 (10.5) 438 (6.1) 132 (1.8) 1 451 (20.1) 7 229 (11.7)
{69.8} {17.3} {9.9} {3.0}
2009 1 550 (22.1) 2 960 (41.2) 734 (10.2) 339 (4.7) 127 (1.8) 1 451 (20.2) 7 184 (11.6)
{71.2} {17.6} {8.1} {3.1}
2010 1 631 (22.3) 3 141 (41.9) 712 (9.5) 398 (5.3) 131 (1.7) 1 466 (19.5) 7 500 (12.1)
{71.7} {16.2} {9.1} {3.0}
2011 1 625 (22.9) 2 990 (40.8) 720 (9.8) 392 (5.4) 147 (2.0) 1 413 (19.3) 7 320 (11.8)
{70.4} {16.9} {9.2} {3.5}
Diagnosis during Screening Yes 438 (36.9) 576 (48.5) 51 (4.3) 16 (1.3) 2 (0.2) 105 (8.8) 1 188 (1.9)
{89.3} {7.9} {2.5} {0.3}
No 3 639 (20.3) 7 832 (43.7) 2 579 (14.4) 963 (5.4) 377 (2.1) 2 532 (14.1) 17 922 (29.0)
{66.6} {21.9} {8.2} {3.2}
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Table 1 Malignant melanoma patients diagnosed between 2002 and 2011 by age at diagnosis, sex, year of diagnosis and UICC
stage, N = 61 895 (Continued)
Unknown 7 372 (17.2) 17 273 (40.4) 4 722 (11.0) 2 576 (6.0) 980 (2.3) 9 862 (23.1) 42 785 (69.1)
{67.6} {18.5} {10.1} {3.8}
Place of residence Eastern Germany 5 531 (22.8) 10 167 (41.9) 3 196 (13.2) 1 251 (5.2) 435 (1.8) 3 672 (15.1) 24 252 (39.2)
{67.6} {21.2} {8.3} {2.9}
Western Germany 5 918 (15.7) 15 514 (41.2) 4 156 (11.0) 2 304 (6.1) 924 (2.5) 8 827 (23.4) 37 643 (60.8)
{67.8} {18.2} {10.1} {4.0}
apercentages refer to row
{} refers to proportions of stages I–IV
bpercentages refer to column
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(2002: 128 cases; 2011: 147 cases) (Table 1, Fig. 2a).
The largest number of patients were diagnosed be-
tween the ages of 65–79 years (n = 22 146, 35.8%) and
the lowest number among those aged 15–34 (n = 4 914,
7.9%) (Table 1). A total of 30 467 men (49.2%) were di-
agnosed with malignant melanoma, compared to 31 428
women (50.8%). In the 50 to 79 years age group, there
were more cases among men (n = 21 316, 54.8%) than
women (n = 17 574, 45.2%). A distinct proportional
change towards older age at diagnosis was observed over
time; the proportion of new cases in the age group
65 years and older increased from 1 765 in 2002 to
3 564 in 2011 (data not shown).Tumour stage distribution
The proportion of cases diagnosed with stage UICC 0 in-
creased from 12.8% in 2002 to 22.9% in 2011 (Table 1).
During the period 2002–2011, the proportions of cases di-
agnosed with pT1, pT2, pT3 and pT4 were 40.0, 13.3, 10.3
and 7.3% respectively (Additional file 2: Table S1). TheFig. 2 Distribution of UICC stages between 2002 and 2011. a Number of c
melanoma patients, stages UICC I-IV, N = 37 947proportion of stage UICC X remained approximately 20%
between 2002 and 2011 (Table 1).
For the analysis of proportional changes in stage distri-
bution, only those cases diagnosed with stage UICC I to
IV were included. The proportion of cases with UICC I
increased from 61.7% in 2002 to 70.4% in 2011 (APC =
0.95, 95% CI 0.52–1.38), while the proportion of stage
UICC II decreased from 25.9% in 2002 to 16.9% in 2011
(APC = −4.33, 95% CI −5.78 to −2.87) (Table 1, Fig. 2b).
No statistically significant trends were found for stage
UICC III and IV between 2002 and 2011.
There was a distinct increase in proportion of cases
diagnosed with stage UICC I between 2008 and 2009
in the age group 15 to 34 years. The proportion of
cases with stage UICC I increased continuously from
64.9% in 2002 to 76.7% in 2011 for the age group
35–64 years at diagnosis, while for those aged 65 years
and older the proportion increased from 52.4 to 62.2%
(Fig. 3). In the age group 65 years and older, there
was a distinct increase in the proportion of cases di-
agnosed with stage UICC I between 2007 (57.9%) and
2008 (63.7%).ases, stages UICC 0-IV and X, N = 61 895. b Proportions of malignant
Fig. 3 Proportion of malignant melanoma cases with stages UICC I to IV (stages UICC 0 and X excluded), by year of diagnosis and age (a 15–34
years, b 35–64 years, c 65 years and older), N = 37 947
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for the complete time period (2002–2011) for the
proportion of stage UICC I for all age groups: 15–34 years
(APC= 1.10, 95% CI 0.62–1.58); 35–64 years (APC= 1.63,
95% CI 1.21–2.05); 65+ years (APC= 2.18, 95% CI 1.16–
3.20). A significant negative trend was found for the
complete time period for the proportion of stage UICC II
for all age groups: 15–34 years (APC= −7.78, 95% CI
−11.96 to −3.39); 35–64 years (APC = −6.31, 95% CI −8.18
to −4.40); 65+ years (APC= −4.38, 95% CI −5.87 to −2.87).
No significant trends were found for UICC stage III and IV
for any of the age groups, except for UICC IV among the
35 to 64 year-olds (APC= −5.52, 95% CI −8.20 to −2.76).
Joinpoint regression only revealed significant continuous
trends over the entire period 2002–2011 in the different
age groups, but no significant trends were revealed for
distinct segments within the 2002–2011 period.
The proportion of cases diagnosed with stage UICC II
over the years was substantially higher among those
65 years and older than among the younger age groups,
while the proportion of cases diagnosed with stage UICC
I decreased with increasing age (Fig. 3). The proportion
of stage UICC II diagnosed between 2002 and 2011 in-
creased with age from 10.8% in the age group 15–34
years to 26.3% in the age group 65 years and older, while
the proportion of UICC I decreased from 79.9 to 60.0%
in these two age groups respectively (Fig. 3).
Among women, the overall proportion of stage UICC I
diagnosed was 70.2%, while the proportion of stage UICC
II was 18.9%. Among men, these proportions were 65.2and 19.8% respectively. The overall proportions of stage
UICC III were 10.7% among men and 8.0% among
women, while the overall proportions of stage UICC IV
were 4.3% among men and 2.9% among women (Table 1).
The proportions of stages UICC I, II, III and IV diag-
nosed in eastern Germany were 67.6, 21.2, 8.3 and 2.9%
respectively, compared to 67.8, 18.2, 10.1 and 4.0% in
western Germany.
Factors influencing stage at diagnosis
To investigate the effect of age, sex, date of diagnosis,
diagnosis during participation in skin cancer screening
and place of residence on the chance of being diagnosed
with malignant melanoma at the prognostically favourable
stage UICC I compared to less favourable stages UICCC
II to IV, univariable and multivariable logistic regression
models were conducted.
In the univariable logistic regression, all explanatory
variables investigated (age, sex, date of diagnosis,
‘diagnosis during screening’ and place of residence) had
a statistically significant influence (p < 0.0001) on the
tumour stage at diagnosis (Table 2). Hence, all variables
were included in the multivariable logistic regression model.
In the multivariable logistic model (Table 2), the
chance of diagnosis at a prognostically favourable stage
(UICC I) decreased with increasing age (OR = 0.97, 95%
CI 0.97–0.97). Women were more likely to have a
favourable prognosis than men (OR = 1.18, 95% CI 1.11–
1.25). Diagnosis with a favourable stage was more likely
in the recent calendar years (OR = 1.05, 95% CI 1.04–
Table 2 Chance of being diagnosed at stage I compared to stages II to IV; for malignant melanoma patients aged 35 years and
above, N = 23 424 (UICC 0 and X excluded; registers with 100% missing values for ‘diagnosis during screening’ excluded)
Univariable logistic regression Multivariable logistic regressionc
Parameter Odds
ratio
95% CIa p valueb Odds
ratio
95% CIa p valueb
Age at diagnosis (years) 0.97 [0.97; 0.97] <.0001 0.97 [0.97; 0.97] <.0001
Sex Male reference reference
Female 1.20 [1.14; 1.27] <.0001 1.18 [1.11; 1.25] <.0001
Date of diagnosis (year) 1.04 [1.03; 1.05] <.0001 1.05 [1.04; 1.06] <.0001
Diagnosis during screening No/unknown reference reference
Yes 3.65 [2.83; 4.71] <.0001 3.24 [2.50; 4.19] <.0001
Place of residence Eastern Germany reference reference
Western Germany 1.28 [1.21; 1.35] <.0001 1.23 [1.16; 1.30] <.0001
aCI: Confidence interval
bWald test
cMultivariable model includes all listed variables
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was also greater if the diagnosis was made during
screening (OR = 3.24, 95% CI 2.50–4.19). Compared to
eastern Germany, patients in western Germany were
more likely to be diagnosed with a prognostically
favourable stage (OR = 1.23, 95% CI 1.16–1.30).
The bootstrap percentile based confidence intervals
confirmed the results of the multivariable logistic regres-
sion. The proportion of missing values for the variable
‘diagnosis during screening’ was however quite high, with
over two thirds (69.1%) having no information. Differences
were found in the structure of the missing values of the
‘diagnosis during screening’ variable in relation to place of
residence between eastern and western Germany
(Additional file 3: Table S2). Complete case analysis as
well as multiple imputation of missing values for the vari-
able ‘diagnosis during screening’ were performed, with the
odds ratio decreasing with multiple imputation. Based on
complete case analysis, the adjusted odds ratio for ‘diagno-
sis during screening’ was 3.57 (95% CI 2.75–4.64) and for
date of diagnosis 1.04 (95% CI 1.03–1.05). Using multiple
imputation for the variable ‘diagnosis during screening’,
the odds ratio was 1.73 (95% CI 1.51–1.98) and for date of
diagnosis 1.04 (95% CI 1.03–1.05) (data not shown).
When the variable ‘diagnosis during screening’ was re-
moved from the multivariable analysis, the odds ratio for
the remaining variables also did not change considerably
(age: 0.97, 95% CI 0.97–0.97; sex: 1.17, 95% CI 1.11–1.24;
date of diagnosis: 1.05, 95% CI 1.04–1.06; place of resi-
dence: 1.23, 95% CI 1.16–1.30).
Relative survival
Among patients with invasive tumours, women had a
higher relative 5-year survival rate (86.2%, 95% CI 85.5–
86.8%) than men (80.5%, 95% CI 79.6–81.4%) (Fig. 4,
Additional file 4: Table S3). The relative 5-year survivalrate decreased with age at diagnosis from 94.6% (95% CI
93.7–95.6%) at 15–34 years to 66.9% (95% CI 64.8–69.1%)
at age 80 years and older (Fig. 4, Additional file 4: Table
S3). The 5-year survival of cases with stage UICC I (96.8%,
95% CI 96.2–97.5%) was over 13 percentage points higher
than the survival of all patients with invasive tumours
(83.4%, 95% CI 82.8–83.9%), while relative survival of the
stages UICC II, III and IV was 74.2% (95% CI 72.8–75.6%),
56.7% (95% CI 54.6–58.8%) and 18.4% (95% CI 15.8–
21.1%), respectively (Fig. 4, Additional file 4: Table S3).
The relative 5-year survival rate after ‘diagnosis during
screening’ was 94.2% (95% CI 89.9–98.5%) which was
higher than for other cases (diagnosis not during screen-
ing: 84.1%, 95% CI 83.0–85.1%; unknown: 82.9%, 95% CI
82.3–83.6%) (Fig. 4, Additional file 4: Table S3). No differ-
ences in survival were found regarding place of residence.
In eastern Germany, the relative 5-year survival rate was
(83.9%, 95% CI 83.0–84.8%) and in western Germany
(83.0%, 95% CI 82.4–83.7%) (Additional file 4: Table S3).
Discussion
An increasing burden of melanoma of the skin has also
been reported for Europe as well as worldwide over the
past decades [25]. This pooled analysis of clinical registry
data showed that the total number of malignant melan-
oma cases diagnosed increased in Germany between
2002 and 2011. A continuous increase in incidence over
the same period has been reported based on data of the
epidemiological cancer registries, which, for eastern
Germany and Bavaria are to a large extent based on the
same cases as were used in our analyses [3].
In addition, cancer documentation and registration, par-
ticularly of stage UICC 0, which has traditionally not been
well documented, has improved in recent years. Thus, the
increase in the absolute number of cases with melanoma in
situ diagnoses may be due to this improved documentation.
Fig. 4 Relative 5-year survival of invasive malignant melanoma patients (UICC 0 excluded) diagnosed between 2002 and 2011, stratified by age
(a), sex (b), UICC stage (c) and ‘diagnosis during screening’ (d), N = 49 351
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remained consistently high between 2002 and 2011. Efforts
therefore need to be directed towards improving the quality
of documentation among physicians.
Although early detection examinations for skin cancer
have been taking place in Germany since 1971, a nation-
wide skin cancer screening program was first introduced
in July 2008 [5]. Uptake of screening in Germany has
however not been high, with only around 30% of eligible
individuals having participated in skin cancer screening
between July 2008 and July 2010 [8]. The German popu-
lation is characterised by an increasing proportion of
older individuals, who are typically diagnosed at more
advanced UICC stages. The effect of demographicchange in terms of potentially diminishing the effective-
ness of skin cancer screening in Germany should there-
fore also be taken into consideration.
Logistic regression models show that the variables
‘diagnosis during screening’ and the date of diagnosis
had a significant impact on the stage at diagnosis. Tu-
mours that were diagnosed during screening (OR = 3.24,
95% CI 2.50–4.19) as well as in the recent calendar years
(OR = 1.05, 95% CI 1.04–1.06) were more likely to be de-
tected in stage UICC I. It can therefore be concluded
that there was a continuous proportional change in
terms of stage at diagnosis over time, rather than a pro-
portional change which could solely be attributed to the
introduction of skin cancer screening in 2008.
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stage distributions over the past decades. In a study con-
ducted in the United States, 70% of malignant melanoma
cases diagnosed between 1988 and 2006 had a thickness
of pT1, compared to 5% with a thickness of pT4 [26]. In
an Australian study, 40% of cases diagnosed between
1990 and 2006 were classified as pT1, compared to 3%
classified as pT4 [27]. Similarly, in our study, 40% of
cases diagnosed between 2002 and 2011 were classified
as pT1, while 7% were classified as pT4.
Our pooled analysis showed that between 2002 and
2011, there was a statistically significant positive trend in
the proportion of cases diagnosed at stage UICC I and a
statistically significant negative trend in the proportion of
cases with UICC II. No statistically significant trends were
found for stages UICC III and IV between 2002 and 2011.
Joinpoint regression showed that there was a signifi-
cant continuous positive trend for the proportion of
stage UICC I and a significant continuous negative trend
for the proportion of stage UICC II in all age groups for
the entire period 2002–2011. No significant trends were
found for any of the stages with regards to distinct time
period segments. Joinpoint regression therefore shows
that among those aged 35–64 years, an age group which
should derive a benefit from screening, the proportion
of stage UICC I rose steadily, with no distinct increase
following the introduction of screening in 2008. The lack
of significant trends, however, does not necessarily mean
that screening had no effect on detecting earlier stages.
We confirmed considerable gender differences in the
distribution of age at diagnosis. Possible explanations in-
clude that melanoma is more likely to occur at an older
age among men than women [28–30], or that the same
tumours were diagnosed later among men than among
women. This may be due to the fact that with regard to
general health seeking behaviour, men are less likely to
attend general health checks than women [31]. The
older age at diagnosis may explain the less favourable
prognoses concerning the UICC stages among men.
The pooled analysis showed that relative survival was
dependent on age, sex, tumour stage and ‘diagnosis dur-
ing screening’. The differences which were found with
regard to overall relative 5-year survival are in line with
other data for Germany [32, 33]. The overall relative 5-
year survival rate in our study was 85.8%, compared to
87.3% in an analysis based on data from the Saarland
Cancer Registry (n = 14 192) [32] and 89.4% based on
data from cancer registries covering 12 out of 16 federal
states and the Münster administrative district of North
Rhine-Westphalia (n = 37 129) [33]. Our pooled analysis,
however, was based on a larger data set and provides
more extensive analyses with regard to a wide range of
variables. In countries such as the USA, Australia, UK
and the Nordic countries, findings were also similar withregard to relative survival depending on stage [34–38].
The 5-year survival rates are found to be higher among
women than men. This has been shown in other studies
conducted in Germany, the United States and the
Netherlands [39–42].
The survival rate for those cases diagnosed during
screening was higher than for the other cases. Selection
bias may however have been introduced as there was a
high number of missing values. Lead time bias also
needs to be taken into consideration, with our data not
being able to provide conclusive evidence in terms of
screening having a positive effect on survival.
Significant differences in survival were not found be-
tween western and eastern Germany. There are however
variations in the extent of follow-up between the regis-
tries, differences in age structure and genetic back-
ground of the populations and differences in incidence
rates between these two regions [11]. It should however
be noted that data from western Germany included in
the analysis were predominantly from Bavaria. In
another German study based on data provided by
population-based epidemiological cancer registries in
both eastern and western Germany for the time period
2002–2006, the 5-year relative survival for malignant
melanoma was 3.3 percentage points lower in eastern
compared to western Germany [43]. Our analysis did
not reveal any significant differences between eastern
and western Germany for this time period (2002–2006).
Strengths and limitations
The analysed data originated from population-based and
hospital-based clinical cancer registries in Germany, pro-
viding an extensive database for malignant melanoma.
Clinical cancer registry data have the advantage of pro-
viding information on various clinical parameters which
epidemiological cancer registries are not able to provide.
For the first time in Germany, analyses on malignant
melanoma were based on such a large data set and pro-
portional changes in tumour stages were investigated
over time. However, not all regions in Germany were in-
cluded in this analysis due to some federal states not
having data from clinical cancer registries for this time
period and some registries not providing their data.
The results of our analyses are robust with regard to
complete case analysis. However, multiple imputation sub-
stantially changed the OR for ‘diagnosis during screening’,
most likely due to the high number of missing values for
this variable. Nevertheless, the association remained statis-
tically significant. Results relating to the ‘diagnosis during
screening’ variable should be treated with caution.
Further research and evaluation regarding the effects of
skin cancer screening in Germany is needed. In addition,
improvement in data quality in terms of more complete no-
tifications and documentation, particularly with regard to
Schoffer et al. BMC Cancer  (2016) 16:936 Page 11 of 12capturing data on whether or not the diagnosis was made
during skin cancer screening, is essential.
Conclusion
Although proportional changes in stage distribution
were found in our analyses, there were no distinct pro-
portional changes which can be directly attributed to the
introduction of skin cancer screening in 2008. No direct
effect of skin cancer screening up to the year 2011 could
therefore be shown.
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